New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus

June 16, 2010

UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving patients' health as quickly as week 12, with the emergence of improvements as early as week 8.

Read the company press release.

 

 

Email This Article To A Friend - Print This Article